Citations (121)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Dorsa Maher, Nagham Ailabouni, Arduino A. Mangoni, Michael D. Wiese & Emily Reeve. (2021) Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opinion on Drug Metabolism & Toxicology 17:1, pages 41-52.
Read now
Read now
Haneen Alrawashdeh, Lama Madi, Arwa Hassan Ahmed Elhada, Afif Ahmed & Dhiaddin Serheed. (2018) A case of probable oxybutynin-induced increase in liver enzymes. Therapeutics and Clinical Risk Management 14, pages 1657-1660.
Read now
Read now
Silvio Aprile, Rossana Canavesi, Rosanna Matucci, Cristina Bellucci, Erika Del Grosso & Giorgio Grosa. (2018) New insights in the metabolism of oxybutynin: evidence of N-oxidation of propargylamine moiety and rearrangement to enaminoketone. Xenobiotica 48:5, pages 478-487.
Read now
Read now
Helena Burden & Paul Abrams. (2016) Urinary incontinence in men: current and developing therapy options. Expert Opinion on Pharmacotherapy 17:5, pages 715-726.
Read now
Read now
Martino Maria Zacchè, Sushma Srikrishna & Linda Cardozo. (2015) Novel targeted bladder drug-delivery systems: a review. Research and Reports in Urology 7, pages 169-178.
Read now
Read now
Martino Maria Zacche, Ilias Giarenis & Linda Cardozo. (2014) Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. Expert Opinion on Investigational Drugs 23:10, pages 1365-1374.
Read now
Read now
Umberto Leone Roberti Maggiore, Stefano Salvatore, Franco Alessandri, Valentino Remorgida, Massimo Origoni, Massimo Candiani, Pier Luigi Venturini & Simone Ferrero. (2012) Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opinion on Drug Metabolism & Toxicology 8:11, pages 1387-1408.
Read now
Read now
G Willy Davila. (2010) Oxybutynin topical gel in the treatment of overactive bladder. Open Access Journal of Urology 2, pages 91-98.
Read now
Read now
Monika Vij, Dudley Robinson & Linda Cardozo. (2010) Emerging drugs for treatment of urinary incontinence. Expert Opinion on Emerging Drugs 15:2, pages 299-308.
Read now
Read now
David R Staskin & Dudley Robinson. (2009) Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opinion on Pharmacotherapy 10:18, pages 3103-3111.
Read now
Read now
Dudley Robinson & Linda Cardozo. (2008) Pharmacotherapy of overactive bladder syndrome. Expert Review of Clinical Pharmacology 1:1, pages 163-175.
Read now
Read now
Roger Dmochowski, David Staskin & Sherron Kell. (2002) Oxybutynin chloride: alterations in drug delivery and improved therapeutic index. Expert Opinion on Pharmacotherapy 3:4, pages 443-454.
Read now
Read now
J. A. Bell & M. H. Tarbit. (1992) Twenty years on: a review of the current practice of drug metabolism and pharmacokinetic studies in the pharmaceutical industry. Xenobiotica 22:7, pages 735-742.
Read now
Read now
Articles from other publishers (108)
Cleo Demeester, Donnia Robins, Angela Elma Edwina, Jos Tournoy, Patrick Augustijns, Ibrahim Ince, Andreas Lehmann, Maria Vertzoni & Jan Frederik Schlender. (2023) Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults – an AGePOP review. European Journal of Pharmaceutical Sciences 188, pages 106496.
Crossref
Crossref
Martin C. Michel, Linda Cardozo, Christopher J. Chermansky, Francisco Cruz, Yasuhiko Igawa, Kyu-Sung Lee, Arun Sahai, Alan J. Wein & Karl-Erik Andersson. (2023) Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. Pharmacological Reviews 75:4, pages 554-674.
Crossref
Crossref
Anirban Ganguly, Shachi Tyagi, Christopher Chermansky, Anthony Kanai, Jonathan Beckel, Mamoru Hashimoto, Kang Jun Cho, Michael Chancellor, Jonathan Kaufman, Naoki Yoshimura & Pradeep Tyagi. (2023) Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options. Drugs & Aging 40:3, pages 241-261.
Crossref
Crossref
Mahnoor F. Malik, Joseph Hogan Randall, Jack G. Campbell, Matthew J. McLaughlin & Joel F. Koenig. (2022) Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder. Topics in Spinal Cord Injury Rehabilitation 28:3, pages 9-14.
Crossref
Crossref
Melanie Kretschmar, Ahmed Abbas Suleiman, Petra Krause, Uwe Albrecht, Raimund Stein, Peter Rubenwolf, Uwe Fuhr & Max Taubert. (2021) A Population Pharmacokinetic Model of (R)‐ and (S‐) Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers. The Journal of Clinical Pharmacology 61:7, pages 961-971.
Crossref
Crossref
Sarah N Hilmer & Carl M J Kirkpatrick. (2021) New Horizons in the impact of frailty on pharmacokinetics: latest developments. Age and Ageing 50:4, pages 1054-1063.
Crossref
Crossref
Shanna C. Trenaman, Susan K. Bowles, Melissa K. Andrew & Kerry Goralski. (2021) The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs. Pharmacology Research & Perspectives 9:3.
Crossref
Crossref
Andreas Wiedemann. 2021. Medikamente in der Urologie. Medikamente in der Urologie
145
169
.
. (2019) Harninkontinenz bei geriatrischen Patienten, Diagnostik und Therapie. Aktuelle Urologie 50:S 01, pages s11-s59.
Crossref
Crossref
Sarah N. Hilmer, Harry Wu & Meggie Zhang. (2019) Biology of frailty: Implications for clinical pharmacology and drug therapy in frail older people. Mechanisms of Ageing and Development 181, pages 22-28.
Crossref
Crossref
Swetalina Pradhan, Bhushan Madke & ChandraSekhar Sirka. (2019) Review of oral anticholinergics in the treatment of palmoplantar hyperhidrosis. Indian Journal of Drugs in Dermatology 5:2, pages 75.
Crossref
Crossref
Shanna C Trenaman, Megan Rideout & Melissa K Andrew. (2019) Sex and gender differences in polypharmacy in persons with dementia: A scoping review. SAGE Open Medicine 7, pages 205031211984571.
Crossref
Crossref
Anthony J. Streeter & Ellen C. Faria. (2017) Analysis of the variability of the pharmacokinetics of multiple drugs in young adult and elderly subjects and its implications for acceptable daily exposures and cleaning validation limits. International Journal of Hygiene and Environmental Health 220:4, pages 659-672.
Crossref
Crossref
Ulrich Schwantes, Joachim Grosse & Andreas Wiedemann. (2015) Refractory overactive bladder: a common problem?. International Urogynecology Journal 26:10, pages 1407-1414.
Crossref
Crossref
Henrik Berg Rasmussen, Ditte Bjerre, Kristian Linnet, Gesche Jürgens, Kim Dalhoff, Hreinn Stefansson, Thomas Hankemeier, Rima Kaddurah-Daouk, Olivier Taboureau, Søren Brunak, Tine Houmann, Pia Jeppesen, Anne Katrine Pagsberg, Kerstin Plessen, Jørgen Dyrborg, Peter Riis Hansen, Poul Erik Hansen, Tim Hughes & Thomas Werge. (2015) Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics 16:6, pages 649-665.
Crossref
Crossref
Shizuo Yamada. (2015) Integration of Pharmacokinetics and Pharmacodynamics Based on the <i>in Vivo</i> Analysis of Drug-receptor Binding生体内での薬物-受容体結合を基盤とした薬物動態と薬効の統合的解析. YAKUGAKU ZASSHI 135:1, pages 137-150.
Crossref
Crossref
Anna Campanati, Stamatis Gregoriou, George Kontochristopoulos & Annamaria Offidani. (2015) Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art. Skin Appendage Disorders 1:1, pages 6-13.
Crossref
Crossref
B. J. Moreira, K. B. Borges, A. R. M. de Oliveira & C. M. de Gaitani. (2015) Analysis of oxybutynin and N-desethyloxybutynin in human urine by dispersive liquid–liquid microextraction (DLLME) and capillary electrophoresis (CE). Analytical Methods 7:20, pages 8763-8770.
Crossref
Crossref
Lucio M.A. Cipullo, Fulvio Zullo, Cosimo Cosimato, Attilio Di Spiezio Sardo, Jacopo Troisi & Maurizio Guida. (2014) Pharmacological Treatment of Urinary Incontinence. Female Pelvic Medicine & Reconstructive Surgery 20:4, pages 185-202.
Crossref
Crossref
A. Qarro, M. Asseban, K. Bazine, M. Najoui, J. Samir, Y. Ouhbi, A. Beddouch, M. Lezrek & M. Alami. (2014) Hyperactivité vésicale : physiopathologie et prise en charge. Journal de Réadaptation Médicale : Pratique et Formation en Médecine Physique et de Réadaptation 34:1, pages 23-34.
Crossref
Crossref
Primal Sharma, Daxesh P. Patel, Mallika Sanyal, Swati Guttikar & Pranav S. Shrivastav. (2014) Parallel achiral–chiral determination of oxybutynin, N-desethyl oxybutynin and their enantiomers in human plasma by LC–MS/MS to support a bioequivalence trial. Journal of Pharmaceutical and Biomedical Analysis 88, pages 81-91.
Crossref
Crossref
Karl-Erik Andersson. 2014. Bladder Dysfunction in the Adult. Bladder Dysfunction in the Adult
121
222
.
Petra Krause, Uwe Fuhr, Jörg Schnitker, Uwe Albrecht, Raimund Stein & Peter Rubenwolf. (2013) Pharmacokinetics of Intravesical Versus Oral Oxybutynin in Healthy Adults: Results of an Open Label, Randomized, Prospective Clinical Study. Journal of Urology 190:5, pages 1791-1797.
Crossref
Crossref
Primal Sharma, Daxesh P. Patel, Mallika Sanyal, Hiren Berawala, Swati Guttikar & Pranav S. Shrivastav. (2013) Simultaneous analysis of oxybutynin and its active metabolite N-desethyl oxybutynin in human plasma by stable isotope dilution LC–MS/MS to support a bioequivalence study. Journal of Pharmaceutical and Biomedical Analysis 84, pages 244-255.
Crossref
Crossref
Kelly Jirschele & Peter K. Sand. (2012) Oxybutynin: past, present, and future. International Urogynecology Journal 24:4, pages 595-604.
Crossref
Crossref
Gary G. Kay, David R. Staskin, Scott MacDiarmid, Marilyn McIlwain & Naomi V. Dahl. (2012) Cognitive Effects of Oxybutynin Chloride Topical Gel in Older Healthy Subjects. Clinical Drug Investigation 32:10, pages 707-714.
Crossref
Crossref
Gary G. Kay, David R. Staskin, Scott MacDiarmid, Marilyn McIlwain & Naomi V. Dahl. (2012) Cognitive Effects of Oxybutynin Chloride Topical Gel in Older Healthy Subjects. Clinical Drug Investigation, pages 1.
Crossref
Crossref
Dudley Robinson & Linda Cardozo. 2012. Dewhurst's Textbook of Obstetrics & Gynaecology. Dewhurst's Textbook of Obstetrics & Gynaecology
635
692
.
Giulio Del Popolo, Marco Mencarini & Vincenzo Li Marzi. (2012) Standard Pharmacological Treatment and New Therapies for Overactive Bladder. Urologia Journal 79:1, pages 6-13.
Crossref
Crossref
Shizuo YamadaShiori KuraokaAyaka OsanoYoshihiko Ito. (2012)
Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of
In Vivo
Drug-Receptor Binding
. International Neurourology Journal 16:3, pages 107.
Crossref
Crossref
Karl-Erik Andersson & Alan J. Wein. 2012. Campbell-Walsh Urology. Campbell-Walsh Urology
1967
2002.e14
.
Roger R. Dmochowski, Diane K. Newman, Peter K. Sand, Delbert C. Rudy, Kim E. Caramelli, Heather Thomas & Gary Hoel. (2011) Pharmacokinetics of Oxybutynin Chloride Topical Gel. Clinical Drug Investigation 31:8, pages 559-571.
Crossref
Crossref
Doreen E. Chung. (2010) Topical Pharmacotherapy for Overactive Bladder. Current Bladder Dysfunction Reports 6:1, pages 20-24.
Crossref
Crossref
Dudley Robinson & Linda Cardozo. 2011. Gynaecology. Gynaecology
813
835
.
Myung Joo KANG, Woo Heon SONG, Byung Ho SHIM, Seung Youn OH, Hyun Young LEE, Eun Young CHUNG, Yesung SOHN & Jaehwi LEE. (2010) Pharmacologically Active Metabolites of Currently Marketed Drugs: Potential Resources for New Drug Discovery and Development. YAKUGAKU ZASSHI 130:10, pages 1325-1337.
Crossref
Crossref
Dudley Robinson & Linda Cardozo. (2010) New drug treatments for urinary incontinence. Maturitas 65:4, pages 340-347.
Crossref
Crossref
Monika VijDudley RobinsonLinda Cardozo. (2010) Overactive Bladder: Diagnosis and Treatment. Women's Health 6:2, pages 297-310.
Crossref
Crossref
G. Willy Davila. (2010) Transdermal Oxybutynin: What Role in the Management of Overactive Bladder?. Clinical Medicine Insights: Therapeutics 2, pages CMT.S2608.
Crossref
Crossref
Akira Yoshida, Tomomi Fujino, Shuji Maruyama, Yoshihiko Ito, Yuko Taki & Shizuo Yamada. (2010) The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Bladder Selectivity Based on In Vivo Drug–Receptor Binding Characteristics of Antimuscarinic Agents for Treatment of Overactive Bladder. Journal of Pharmacological Sciences 112:2, pages 142-150.
Crossref
Crossref
Christopher R. Chapple. (2009) Oxybutynin topical gel for overactive bladder. Nature Reviews Urology 6:7, pages 351-352.
Crossref
Crossref
Khanh Tran, Robert M. Levin & Shaker A. Mousa. (2009) Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction. Advances in Urology 2009, pages 1-10.
Crossref
Crossref
Karl-Erik Andersson, Claudius Fullhase & Roberto Soler. (2008) Urothelial effects of oral agents for overactive bladder. Current Urology Reports 9:6, pages 459-464.
Crossref
Crossref
Marci L. Chew, Benoit H. Mulsant, Bruce G. Pollock, Mark E. Lehman, Andrew Greenspan, Ramy A. Mahmoud, Margaret A. Kirshner, Denise A. Sorisio, Robert R. Bies & Georges Gharabawi. (2008) Anticholinergic Activity of 107 Medications Commonly Used by Older Adults. Journal of the American Geriatrics Society 56:7, pages 1333-1341.
Crossref
Crossref
Melinda Wuest. 2008. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
13
.
Sushma Srikrishna, Dudley Robinson, Linda Cardozo & Maria Vella. (2007) Management of overactive bladder syndrome. Postgraduate Medical Journal 83:981, pages 481-486.
Crossref
Crossref
Joseph L. Reiz, Paulette Salem & Andrew C. Darke. (2007) Pharmacokinetics and Pharmacodynamics of Once-Daily Controlled-Release Oxybutynin and Immediate-Release Oxybutynin. The Journal of Clinical Pharmacology 47:3, pages 351-357.
Crossref
Crossref
Ragnar Asplund. (2007) Pharmacotherapy for Nocturia in the Elderly Patient. Drugs & Aging 24:4, pages 325-343.
Crossref
Crossref
H. Mallory Reeves, Eric S. Rovner & Alan J. Wein. 2007. Female Urology. Female Urology
177
199
.
Ananias Diokno & Michael Ingber. (2006) Oxybutynin in Detrusor Overactivity. Urologic Clinics of North America 33:4, pages 439-445.
Crossref
Crossref
Martin C. Michel & Sharath S. Hegde. (2006) Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?. Naunyn-Schmiedeberg's Archives of Pharmacology 374:2, pages 79-85.
Crossref
Crossref
Eric S Rovner & Alan J Wein. (2016) Antimuscarinic Drugs for the Treatment of Female Urinary Incontinence. Women's Health 2:2, pages 251-265.
Crossref
Crossref
Dudley RobinsonLinda Cardozo. (2016) Pharmacological Treatment for Overactive Bladder in Women. Women's Health 2:2, pages 239-250.
Crossref
Crossref
Tomomi Oki, Ayako Toma-Okura & Shizuo Yamada. (2006) Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration, and Salivary Secretion. Journal of Pharmacology and Experimental Therapeutics 316:3, pages 1137-1145.
Crossref
Crossref
Shuji Maruyama, Tomomi Oki, Atsushi Otsuka, Hitoshi Shinbo, Seiichiro Ozono, Shinji Kageyama, Yuuki Mikami, Isao Araki, Masayuki Takeda, Keisuke Masuyama & Shizuo Yamada. (2006) Human Muscarinic Receptor Binding Characteristics of Antimuscarinic Agents to Treat Overactive Bladder. Journal of Urology 175:1, pages 365-369.
Crossref
Crossref
Hashim Hashim & Paul Abrams. (2005) Treatment options for the overactive bladder syndrome. Therapy 2:6, pages 921-936.
Crossref
Crossref
Hashim Hashim & Paul Abrams. (2005) Treatment options for the overactive bladder syndrome. Therapy 2:6, pages 921-936.
Crossref
Crossref
Roger R. Dmochowski, Victor Nitti, David Staskin, Karl Luber, Rodney Appell & G. Willy Davila. (2005) Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World Journal of Urology 23:4, pages 263-270.
Crossref
Crossref
Tomomi Oki, Akihiro Kawashima, Masayuki Uchida & Shizuo Yamada. (2005) In vivo demonstration of muscarinic receptor binding activity of N-desethyl-oxybutynin, active metabolite of oxybutynin. Life Sciences 76:21, pages 2445-2456.
Crossref
Crossref
Stefano Salvatore, Vikram Khullar, Linda Cardozo, Rodolfo Milani, Stavros Athanasiou & Con Kelleher. (2005) Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. European Journal of Obstetrics & Gynecology and Reproductive Biology 119:2, pages 237-241.
Crossref
Crossref
Roger Dmochowski. (2005) Improving the Tolerability of Anticholinergic Agents in the Treatment of Overactive Bladder. Drug Safety 28:7, pages 583-600.
Crossref
Crossref
Rashmi R. Shah. (2004) Drug development and use in the elderly: search for the right dose and dosing regimen. British Journal of Clinical Pharmacology 58:5, pages 452-469.
Crossref
Crossref
TOMOMI OKI, RYOHEI KIMURA, MOTOAKI SAITO, IKUO MIYAGAWA & SHIZUO YAMADA. (2004) DEMONSTRATION OF BLADDER SELECTIVE MUSCARINIC RECEPTOR BINDING BY INTRAVESICAL OXYBUTYNIN TO TREAT OVERACTIVE BLADDER. Journal of Urology 172:5, pages 2059-2064.
Crossref
Crossref
Manthena V.S. Varma, Aditya M. Kaushal & Sanjay Garg. (2004) Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations. Journal of Pharmaceutical and Biomedical Analysis 36:3, pages 669-674.
Crossref
Crossref
Hashim Hashim & Paul Abrams. (2004) Drug Treatment of Overactive Bladder. Drugs 64:15, pages 1643-1656.
Crossref
Crossref
M Asif A Siddiqui, Caroline M Perry & Lesley J Scott. (2004) Oxybutynin Extended-Release. Drugs 64:8, pages 885-912.
Crossref
Crossref
Masayuki Uchida, Megumi Koganei, Natsuko Murata & Taketo Yamaji. (2004) Effects of 4-Ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate Hydrochloride, a Metabolite of Oxybutynin, on Bladder Specimens and Rhythmic Bladder Contraction in Rats in Comparison With Oxybutynin. Journal of Pharmacological Sciences 94:2, pages 122-128.
Crossref
Crossref
Karl-Erik Andersson. (2004) Antimuscarinics for treatment of overactive bladder. The Lancet Neurology 3:1, pages 46-53.
Crossref
Crossref
Eric S. Rovner & Alan J. Wein. (2003) Update on overactive bladder: Pharmacologic approaches on the horizon. Current Urology Reports 4:5, pages 385-390.
Crossref
Crossref
Jurandir Fernando Comar, Fumie Suzuki-Kemmelmeier & Adelar Bracht. (2003) The Action of Oxybutynin on Haemodynamics and Metabolism in the Perfused Rat Liver. Pharmacology & Toxicology 93:3, pages 147-152.
Crossref
Crossref
Alexander Staab, Barbara S Schug, Véronique Larsimont, Martina Elze, Daniela Thümmler, Ernst Mutschler & Henning Blume. (2003) Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses. European Journal of Pharmaceutical Sciences 18:2, pages 121-128.
Crossref
Crossref
Mike B. Siroky. (2003) Neurological disorders Cerebrovascular disease and Parkinsonism. Urologic Clinics of North America 30:1, pages 27-47.
Crossref
Crossref
David R P Guay. (2003) Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence. Clinical Pharmacokinetics 42:14, pages 1243-1285.
Crossref
Crossref
Lynne M Bang, Stephanie E Easthope & Caroline M Perry. (2003) Transdermal Oxybutynin. Drugs & Aging 20:11, pages 857-864.
Crossref
Crossref
Karl-Erik Andersson. 2003. Female Pelvic Medicine and Reconstructive Pelvic Surgery. Female Pelvic Medicine and Reconstructive Pelvic Surgery
245
267
.
ROGER R. DMOCHOWSKI, G. WILLY DAVILA, NORMAN R. ZINNER, MARC C. GITTELMAN, DANIEL R. SALTZSTEIN, SYDNEY LYTTLE & STEVEN W. SANDERS. (2002) Efficacy and Safety of Transdermal Oxybutynin in Patients With Urge and Mixed Urinary Incontinence. The Journal of Urology, pages 580-586.
Crossref
Crossref
Roger R. Dmochowski, G. Willy Davila, Norman R. Zinner, Marc C. Gittelman, Daniel R. Saltzstein, Sydney Lyttle & Steven W. Sanders. (2002) Efficacy and Safety of Transdermal Oxybutynin in Patients With Urge and Mixed Urinary Incontinence. Journal of Urology 168:2, pages 580-586.
Crossref
Crossref
Lisbeth Nilvebrant. (2002) Tolterodine and its Active 5-Hydroxymethyl Metabolite: Pure Muscarinic Receptor Antagonists. Pharmacology & Toxicology 90:5, pages 260-267.
Crossref
Crossref
Martin C. Michel. (2002) A Benefit-Risk Assessment of Extended-Release Oxybutynin. Drug Safety 25:12, pages 867-876.
Crossref
Crossref
Eric S. Rovner & Alan J. Wein. (2002) Once-Daily, Extended-Release Formulations of Antimuscarinic Agents in the Treatment of Overactive Bladder: A Review. European Urology 41:1, pages 6-14.
Crossref
Crossref
SAVINO M. DI STASI, ANTONELLA GIANNANTONI, PIERLUIGI NAVARRA, GIOVANNI CAPELLI, LUIGI STORTI, MASSIMO PORENA & ROBERT L. STEPHEN. (2001) INTRAVESICAL OXYBUTYNIN:. The Journal of Urology, pages 2232-2236.
Crossref
Crossref
SAVINO M. DI STASI, ANTONELLA GIANNANTONI, PIERLUIGI NAVARRA, GIOVANNI CAPELLI, LUIGI STORTI, MASSIMO PORENA & ROBERT L. STEPHEN. (2001) INTRAVESICAL OXYBUTYNIN: MODE OF ACTION ASSESSED BY PASSIVE DIFFUSION AND ELECTROMOTIVE ADMINISTRATION WITH PHARMACOKINETICS OF OXYBUTYNIN AND N-DESETHYL OXYBUTYNIN. Journal of Urology 166:6, pages 2232-2236.
Crossref
Crossref
G. W. DAVILA, C. A. DAUGHERTY & S. W. SANDERS. (2001) A SHORT-TERM, MULTICENTER, RANDOMIZED DOUBLE-BLIND DOSE TITRATION STUDY OF THE EFFICACY AND ANTICHOLINERGIC SIDE EFFECTS OF TRANSDERMAL COMPARED TO IMMEDIATE RELEASE ORAL OXYBUTYNIN TREATMENT OF PATIENTS WITH URGE URINARY INCONTINENCE. THE JOURNAL OF UROLOGY, pages 140-145.
Crossref
Crossref
G.W. DAVILA, C.A. DAUGHERTY & S.W. SANDERS. (2001) A SHORT-TERM, MULTICENTER, RANDOMIZED DOUBLE-BLIND DOSE TITRATION STUDY OF THE EFFICACY AND ANTICHOLINERGIC SIDE EFFECTS OF TRANSDERMAL COMPARED TO IMMEDIATE RELEASE ORAL OXYBUTYNIN TREATMENT OF PATIENTS WITH URGE URINARY INCONTINENCE. Journal of Urology 166:1, pages 140-145.
Crossref
Crossref
G. Lose & J.P. Nørgaard. (2001) Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. BJU International 87:9, pages 767-773.
Crossref
Crossref
Gayatri Sathyan, Weiting Hu & Suneel K. Gupta. (2013) Lack of Effect of Food on the Pharmacokinetics of an Extended‐Release Oxybutynin Formulation. The Journal of Clinical Pharmacology 41:2, pages 187-192.
Crossref
Crossref
Savino M. Di Stasi, Antonella Giannantoni, Giuseppe Vespasiani, Pierluigi Navarra, Giovanni Capelli, Renato Massoud & Robert L. Stephen. (2001) INTRAVESICAL ELECTROMOTIVE ADMINISTRATION OF OXYBUTYNIN IN PATIENTS WITH DETRUSOR HYPERREFLEXIA UNRESPONSIVE TO STANDARD ANTICHOLINERGIC REGIMENS. Journal of Urology 165:2, pages 491-498.
Crossref
Crossref
Alexander Staab, Steffen Scheithauer, Hiltrud Fieger-Büschges, Ernst Mutschler & Henning Blume. (2001) A validated high-performance liquid chromatographic assay for the simultaneous determination of denaverine and its N-monodemethyl metabolite in human plasma. Journal of Chromatography B: Biomedical Sciences and Applications 751:2, pages 221-228.
Crossref
Crossref
Stephen E Jones, Lesya M Shuba, Pavel Zhabyeyev, John R McCullough & Terence F McDonald. (2009)
Differences in the effects of urinary incontinence agents S‐oxybutynin and terodiline on cardiac K
+
currents and action potentials
. British Journal of Pharmacology 131:2, pages 245-254.
Crossref
Crossref
CHRISTOPHER R. CHAPPLE. (2014) MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER. BJU International 85:S3, pages 33-46.
Crossref
Crossref
Christopher R Chapple. (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55:5, pages 33-46.
Crossref
Crossref
K-E. Andersson. (2000) Drug therapy for urinary incontinence. Best Practice & Research Clinical Obstetrics & Gynaecology 14:2, pages 291-313.
Crossref
Crossref
Stephen E. Jones, Yuji Kasamaki, Lesya M. Shuba, Toshitsugu Ogura, John R. McCullough & Terence F. McDonald. (2000) Analysis of the Electrophysiologic Effects of Short-Term Oxybutynin on Guinea Pig and Rabbit Ventricular Cells. Journal of Cardiovascular Pharmacology 35:2, pages 334-340.
Crossref
Crossref
Andersson, Appell, Cardozo, Chapple, Drutz, Finkbeiner, Haab & Vela Navarrete. (2001) The pharmacological treatment of urinary incontinence. BJU International 84:9, pages 923-947.
Crossref
Crossref
Renato Massoud, Giorgio Federici, Stefania Casciani, Savino M. Di Stasi, Giorgio Fucci, Antonella Giannantoni & Claudio Cortese. (1999) Extraction and determination of oxybutynin in human bladder samples by reversed-phase high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications 734:1, pages 163-167.
Crossref
Crossref
Marvin M. Goldenberg. (1999) An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clinical Therapeutics 21:4, pages 634-642.
Crossref
Crossref
Suneel K. GuptaGayatri Sathyan. (2013) Pharmacokinetics of an Oral Once‐a‐Day Controlled‐Release Oxybutynin Formulation Compared with Immediate‐Release Oxybutynin. The Journal of Clinical Pharmacology 39:3, pages 289-296.
Crossref
Crossref
Wagg & Malone‐Lee. (2002) The management of urinary incontinence in the elderly. British Journal of Urology 82:S1, pages 11-17.
Crossref
Crossref
Åmark, Eksborg, Juneskans, Bussman & Palm. (2002) Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder. British Journal of Urology 82:6, pages 859-864.
Crossref
Crossref
Helmut Madersbacher, Said Awad, Magnus Fall, R. A. Janknegt, Manfred Stöhrer & Boye Weisner. (2014) Urge Inkontinenz beim älteren Menschen — supraspinale Reflexinkontinenz. Der Urologe B 38:8, pages S10-S18.
Crossref
Crossref
GUNNAR BUYSE, KRISTIAN WALDECK, CARLA VERPOORTEN, HENRIK BJORK, PAUL CASAER & KARL-ERIK ANDERSSON. (1998) INTRAVESICAL OXYBUTYNIN FOR NEUROGENIC BLADDER DYSFUNCTION. The Journal of Urology, pages 892-896.
Crossref
Crossref
GUNNAR BUYSE, KRISTIAN WALDECK, CARLA VERPOORTEN, HENRIK BJORK, PAUL CASAER & KARL-ERIK ANDERSSON. (1998) INTRAVESICAL OXYBUTYNIN FOR NEUROGENIC BLADDER DYSFUNCTION: LESS SYSTEMIC SIDE EFFECTS DUE TO REDUCED FIRST PASS METABOLISM. Journal of Urology 160:3 Part 1, pages 892-896.
Crossref
Crossref
Eeva Lukkari, Päivi Taavitsainen, Auni Juhakoskr & Olavi Pelkonen. (2009) Cytochrome P450 Specificity of Metabolism and Interactions of Oxybutynin in Human Liver Microsomes. Pharmacology & Toxicology 82:4, pages 161-166.
Crossref
Crossref
Ira R. Katz, Laura Prouty Sands, Warren Bilker, Suzanne DiFilippo, Alice Boyce & Kristina D'Angelo. (1998) Identification of Medications That Cause Cognitive Impairment in Older People: The Case of Oxybutynin Chloride. Journal of the American Geriatrics Society 46:1, pages 8-13.
Crossref
Crossref
Eeva Lukkari, Kari Aranko, Auni Juhakoski, Tiina Hakonen & Pertti J. Neuvonen. (2009) Effect of Time Interval between Food and Drug Ingestion on the Absorption of Oxybutynin from a Controlled‐Release Tablet. Pharmacology & Toxicology 81:1, pages 31-34.
Crossref
Crossref
Kristian Waldeck, Bengt Larsson & Karl-Erik Andersson. (1997) Comparison of Oxybutynin and its Active Metabolite, N-Desethyl-Oxybutynin, in the Human Detrusor and Parotid Gland. The Journal of Urology, pages 1093-1097.
Crossref
Crossref
Kristian Waldeck, Bengt Larsson & Karl-Erik Andersson. (1997) Comparison of Oxybutynin and its Active Metabolite, N-Desethyl-Oxybutynin, in the Human Detrusor and Parotid Gland. Journal of Urology 157:3, pages 1093-1097.
Crossref
Crossref
Tanja Alebic-Kolbah & A. Paul Zavitsanos. (1997) Chiral bioanalysis by normal phase high-performance liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. Journal of Chromatography A 759:1-2, pages 65-77.
Crossref
Crossref
Etsuko Miyamoto, Yoko Demizu, Yoshifumi Murata, Yutaka Yamada, Susumu Kawashima, Hitoshi Kontani & Takeshi Sakai. (1993) High-performance liquid chromatographic preparation of oxybutynin enantiomers on a chiral stationary phase. Journal of Chromatography A 653:1, pages 135-137.
Crossref
Crossref